Forecast

The analysts' average price target is +36,63€ (+192,11%). The median is +38,63€ (+208,05%).

Buy	3
Hold	3
Sell	1

News Go to news feed

Lyell Immunoncology presents strong study data for ronde-cel and LYL273 and outlines regulatory milestones

At the cell therapy conference, Lyell presented new clinical data on its programs ronde-cel (CD19/20 CAR-T for large B‑cell lymphoma) and LYL273 (CAR‑T for metastatic colorectal cancer). Ronde‑cel showed an overall response rate of 93% and a complete response rate of 76% in 100 patients, with a median progression‑free survival of 18 months and a favorable safety profile. LYL273 achieved overall response rates of 50% in US patients and 40% in the original China cohort; a prophylactic GI therapy reduced severe diarrhea from 55% to 10% in a small comparative group. The company emphasizes production readiness with in‑house manufacturing and is targeting an end‑of‑Phase‑I meeting with the FDA by year‑end, along with several data uploads and potential approval pathways. » More on de.investing.com
Lyell shows positive safety data for Ronde-cel in large B‑cell lymphoma

Lyell presented safety and translational data from the phase‑1/2 study of Ronde‑cel in relapsed/refractory large B‑cell lymphoma at EHA. As of May 5, 2026, 108 patients had been treated; the manufacturing success rate was 97%. No grade 3 or higher cytokine release syndrome was reported; severe neurotoxicities (grade ≥3) occurred in 8% of patients with dexamethasone prophylaxis versus 16% without prophylaxis. Translational analyses identified cytotoxic effector cells with memory genes more often in patients with durable responses >12 months. Lyell has a market capitalization of $314 million, reported a negative EBITDA of $176 million, and plans regulatory data/analyses for mid to late 2026 and mid/second half 2027. » More on de.investing.com
Lyell presents Ronde-cel data at EHA: safety analysis and biomarker findings

At the 2026 EHA congress, Lyell is presenting two posters on Ronde-cel (dual CD19/CD20 CAR‑T), including an updated safety analysis and translational findings on long‑lived cytotoxic T cells. Ronde-cel is being evaluated in two registration‑relevant trials for relapsed/refractory large B‑cell lymphoma; PiNACLE is expected to deliver registration‑relevant data in mid‑2027 and a BLA submission is planned for 2027. The stock fell 25% last week, and the company shows a high current ratio alongside rapid cash burn. » More on de.investing.com

Financials

In the last quarter, LYELL IMMUNOPHARMA INC had revenue of 3.50k€ and net profit of −39.21m€

(EUR)	Jun 2026	YoY
Revenue	+3.50k	48,36%
Gross profit	+3.50k	48,36%
Net profit	−39.21m	8,29%
EBITDA	−37.27m	3,21%

Fundamentals

Metric	Value
Market capitalization	+325.82m€
Number of shares	24.50m
52-week high/low	+38,63€ - +9,24€
Dividends	No
Beta	-0,07
P/E ratio	−0,97
PEG ratio	+0,01
P/B ratio	+1,55
P/S ratio	+14.058,24

Company profile

Lyell Immunopharma, Inc. ist ein Unternehmen, das sich mit der Reprogrammierung von T-Zellen befasst und T-Zell-Therapien für Patienten mit soliden Tumoren entwickelt. Das Unternehmen entwickelt Therapien unter Verwendung von Technologieplattformen wie Gen-R, einer ex vivo genetischen Reprogrammierungstechnologie zur Überwindung der T-Zell-Erschöpfung, und Epi-R, einer ex vivo epigenetischen Reprogrammierungstechnologie zur Erzeugung von T-Zellpopulationen mit dauerhafter Stammfähigkeit. Die Pipeline des Unternehmens umfasst LYL797, einen T-Zell-Produktkandidaten für die Behandlung von nicht-kleinzelligem Lungenkrebs und dreifach negativem Brustkrebs; LYL845, das auf verschiedene solide Tumore abzielt; und NY-ESO-1 für synoviales Sarkom und andere solide Tumorindikationen. Für das Programm NY-ESO-1 schloss das Unternehmen eine Forschungs- und Entwicklungskooperation und eine Lizenzvereinbarung mit GlaxoSmithKline ab. Lyell Immunopharma, Inc. wurde im Jahr 2018 gegründet und hat seinen Hauptsitz in South San Francisco, Kalifornien.